Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Crystallin beta-gamma domain containing 1 (CRYBG1)
- Target
- CRYBG1
- Molecular classification
- Other (structural protein, crystallin family)
01
Overview
Crystallin beta-gamma domain containing 1 (CRYBG1), also known as Absent in melanoma 1 protein (AIM1), is a human structural protein that contains beta-gamma crystallin domains. Its primary function is believed to act as a tumor suppressor, particularly in malignant melanoma, exerting effects through interactions with the cytoskeleton. Proteins of the beta-gamma crystallin family typically play structural roles, and CRYBG1 may also possess carbohydrate binding capability. Disease association is mainly reported for melanoma, though no direct drugs or established therapeutic interventions target this molecule[4][3][12][13][5].
- Other names
- AIM1Absent in melanoma 1 proteinSuppression of tumorigenicity 4ST4Beta/gamma crystallin domain-containing protein 1Crystallin β-γ domain containing 1
02
Biological functions
Tumor suppressionPossible carbohydrate bindingCytoskeletal interactionPossibly stress response, protein folding, molecular chaperoning (as general domain features)
03
Disease associations
Cancer (notably melanoma suppression)
04
Biomarkers
Melanoma (proposed tumor suppressor and candidate biomarker for disease involvement)
Beyond the preview
Go deeper on Crystallin beta-gamma domain containing 1 (CRYBG1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Crystallin beta-gamma domain containing 1 (CRYBG1).